Drugs, non-drugs, and disease category specificity: organ effects by ligand pharmacology1

Important understanding can be gained from using molecular biology-based and chemistry-based techniques together. Bayesian classifiers have thus been developed in the present work using several statistically significant molecular properties of compiled datasets of drugs and non-drugs, including their disease category or organ. The results show they provide a useful classification and simplicity of several different ligand efficiencies and molecular properties. Early recall of drugs among non-drugs using the classifiers as a ranking tool is also provided. As the chemical space of compounds is addressed together with their anatomical characterization, chemical libraries can be improved to select for specific organ or disease. Eventually, by including even finer detail, the method may help in designing libraries with specific pharmacological or toxicological target chemical space. Alternatively, a lack of statistically significant differences in property density distributions may help in further describing compounds with possibility of activity on several organs or disease groups, and given their very similar or considerably overlapping chemical space, therefore wanted or unwanted side-effects. The overlaps between densities for several properties of organs or disease categories were calculated by integrating the area under the curves where they intersect. The naïve Bayesian classifiers are readily built, fast to score, and easily interpretable.

[1]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[2]  Yasuo Ohashi,et al.  Overlap coefficient for assessing the similarity of pharmacokinetic data between ethnically different populations , 2005, Clinical trials.

[3]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[4]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[5]  Uko Maran,et al.  Drug efficiency indices for improvement of molecular docking scoring functions , 2010, J. Comput. Chem..

[6]  Alfonso T García-Sosa,et al.  Free Energy Calculations of Mutations Involving a Tightly Bound Water Molecule and Ligand Substitutions in a Ligand‐Protein Complex , 2010, Molecular informatics.

[7]  Uko Maran,et al.  Combined Approach Using Ligand Efficiency, Cross-Docking, and Antitarget Hits for Wild-Type and Drug-Resistant Y181C HIV-1 Reverse Transcriptase , 2011, J. Chem. Inf. Model..

[8]  Yuan Zhao,et al.  Computation of Octanol-Water Partition Coefficients by Guiding an Additive Model with Knowledge , 2007, J. Chem. Inf. Model..

[9]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[10]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[11]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[12]  Meir Glick,et al.  Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..

[13]  Renxiao Wang,et al.  The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. , 2004, Journal of medicinal chemistry.

[14]  J. Chambers A Concise Course in Advanced Level Statistics , 1984 .

[15]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[16]  Uko Maran,et al.  Docking and Virtual Screening Using Distributed Grid Technology , 2009 .

[17]  O. Taboureau,et al.  The impact of network biology in pharmacology and toxicology , 2012, SAR and QSAR in environmental research.

[18]  Uko Maran,et al.  DrugLogit: Logistic Discrimination between Drugs and Nondrugs Including Disease-Specificity by Assigning Probabilities Based on Molecular Properties , 2012, J. Chem. Inf. Model..

[19]  I. Kuntz,et al.  The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Junwei Zhang,et al.  Development of KiBank, a database supporting structure-based drug design , 2004, Comput. Biol. Chem..

[21]  A. Bender,et al.  Modeling Promiscuity Based on in vitro Safety Pharmacology Profiling Data , 2007, ChemMedChem.

[22]  U. Maran,et al.  Molecular property filters describing pharmacokinetics and drug binding. , 2012, Current medicinal chemistry.

[23]  Alfonso T. García-Sosa,et al.  Structure-based calculation of drug efficiency indices , 2007, Bioinform..

[24]  Michael J. Keiser,et al.  The Chemical Basis of Pharmacology , 2010, Biochemistry.

[25]  Uko Maran,et al.  Disease‐Specific Differentiation Between Drugs and Non‐Drugs Using Principal Component Analysis of Their Molecular Descriptor Space , 2012, Molecular informatics.

[26]  J. Ladbury,et al.  Survey of the year 2005: literature on applications of isothermal titration calorimetry , 2007, Journal of molecular recognition : JMR.

[27]  B. Matthews Comparison of the predicted and observed secondary structure of T4 phage lysozyme. , 1975, Biochimica et biophysica acta.